FcRn Inhibitors Play an Evolving Role in Myasthenia Gravis Treatment

By News Health
2 hours Ago

(MedPage Today) — Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), rozanolixizumab (Rystiggo…

Source link : https://www.medpagetoday.com/spotlight/gmg/119911

Author :

Publish date : 2026-02-17 18:18:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Are Fancy Blood Tests to Find Disease All They're Cracked Up to Be?

New Topical PDE4 Inhibitor Gets Green Light From FDA

Navigating Difficult Questions in Breast Cancer Care

It Always Could Have Been One of Us

How Much Efficacy Do Statin Users Demand in Primary Prevention?

Rheumatoid Arthritis: How Best to Gauge ILD Risk in Light of Comorbidities?